Get the Stockscreener App
14.80
21.11%
2.58
After Hours:
14.14
-0.66
-4.46%
Transcode Therapeutics Inc stock is traded at $14.80, with a volume of 7.49M.
It is up +21.11% in the last 24 hours and up +36.28% over the past month.
TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.
See More
Previous Close:
$12.22
Open:
$18.71
24h Volume:
7.49M
Relative Volume:
52.96
Market Cap:
$12.34M
Revenue:
-
Net Income/Loss:
$-14.93M
P/E Ratio:
-0.0556
EPS:
-266.137
Net Cash Flow:
$-15.87M
1W Performance:
+39.49%
1M Performance:
+36.28%
6M Performance:
+36.23%
1Y Performance:
-96.68%
1-Day Range:
$13.18
$20.99
1-Week Range:
$10.32
$20.99
52-Week Range:
$6.1478
$739.20
Transcode Therapeutics Inc Stock (RNAZ) Company Profile
Name
Transcode Therapeutics Inc
Sector
Industry
Phone
857-301-6857
Address
6 LIBERTY SQUARE, BOSTON
Compare RNAZ with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RNAZ
Transcode Therapeutics Inc
|
14.80 | 10.19M | 0 | -14.93M | -15.87M | -266.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.15 | 105.19B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
450.68 | 60.24B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.86 | 61.82B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
798.94 | 49.09B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
351.09 | 37.52B | 4.56B | -176.77M | 225.30M | -1.7177 |
Transcode Therapeutics Inc Stock (RNAZ) Latest News
TransCode Therapeutics, Inc. (RNAZ) Stock :Soars as $25M Investment and Polynoma Acquisition Ignite Growth Prospects - parameter.io
TransCode Therapeutics To Acquire Polynoma; $25M Financing By a Subsidiary Of CK Life Sciences - citybiz
TransCode Makes Bold Bet On Melanoma Vaccine With Polynoma Buyout - Benzinga
Transcode announces the acquisition of Polynoma and a $25 mln financing by subsidiary of CK Life Sciences - MarketScreener
TransCode Acquires Polynoma, Secures $25M Strategic Investment | RNAZ Stock News - Stock Titan
TransCode Therapeutics To Acquire Polynoma, Receive $25M Investment To Advance Key Asset - Stocktwits
Chart based exit strategy for TransCode Therapeutics Inc.2025 Historical Comparison & Expert Verified Stock Movement Alerts - newser.com
Strategies to average down on TransCode Therapeutics Inc.2025 Breakouts & Breakdowns & Risk Managed Investment Entry Signals - newser.com
TransCode Therapeutics Amends Patent License Agreement - TipRanks
TransCode Therapeutics (NASDAQ:RNAZ) Trading Down 1.5% – What’s Next? - Defense World
Will TransCode Therapeutics Inc. stock go up soonMarket Activity Report & Growth Oriented Trade Recommendations - newser.com
Is TransCode Therapeutics Inc. stock bottoming outJuly 2025 Big Picture & Real-Time Volume Analysis Alerts - newser.com
TransCode Therapeutics Passes Key Proposals at Annual Meeting - MSN
How hedge fund analytics apply to TransCode Therapeutics Inc. stock2025 Top Decliners & Reliable Entry Point Alerts - newser.com
Developing predictive dashboards with TransCode Therapeutics Inc. dataMarket Sentiment Review & Safe Capital Allocation Plans - newser.com
TransCode Therapeutics Inc Stock Analysis and ForecastSupport Level Holds & Our Picks = Your Future Gains - earlytimes.in
What analysts say about TransCode Therapeutics Inc stockShort-Term Trading Alerts & Build a Smarter Portfolio Right Now - earlytimes.in
A activity2025 Technical Patterns & Real-Time Buy Signal Notifications - newser.com
What to expect from CPSH in the next 30 daysWatch List & High Accuracy Swing Entry Alerts - newser.com
Is Mineralys Therapeutics Inc. stock poised for growthJuly 2025 Reactions & Free Safe Capital Growth Stock Tips - newser.com
NGVT stock trend outlook and recovery pathMarket Movement Recap & Safe Entry Momentum Tips - newser.com
How high can TransCode Therapeutics Inc. stock goCPI Data & Safe Capital Growth Tips - newser.com
Published on: 2025-09-21 07:32:21 - خودرو بانک
Macro Review: Why is TransCode Therapeutics Inc stock going downWeekly Profit Report & Real-Time Volume Analysis - khodrobank.com
Loss Report: Is TransCode Therapeutics Inc subject to activist investor interest2025 Geopolitical Influence & High Conviction Trade Alerts - خودرو بانک
Applying Wyckoff theory to TransCode Therapeutics Inc. stockFed Meeting & Risk Managed Investment Entry Signals - newser.com
Earnings Miss: What makes TransCode Therapeutics Inc stock attractive today2025 Market Overview & Community Trade Idea Sharing - khodrobank.com
Market Overview: What are analysts price targets for TransCode Therapeutics Inc2025 Buyback Activity & Risk Controlled Swing Alerts - khodrobank.com
Growth Review: Is TransCode Therapeutics Inc undervalued by DCF analysis2025 Bull vs Bear & Verified Chart Pattern Trade Signals - خودرو بانک
Institution Moves: Will SOBO benefit from geopolitical trendsMarket Risk Report & Scalable Portfolio Growth Methods - خودرو بانک
Transcode Therapeutics Inc Stock (RNAZ) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.05%
4.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):